FDA Brief

Warning letters Drugs

FDA warning letter to

TCT Nutraceuticals SDN. BHD

High riskIssued Jun 5, 2024Posted Jun 11, 2024Center for Drug Evaluation and Research | CDER

FDA warns TCT Nutraceuticals over manufacturing-rule failures in OTC hand sanitizer, including no methanol testing.

What happened

FDA reviewed records TCT submitted after FDA's June 16, 2022, and July 8, 2022, requests under section 704(a)(4) of the FD&C Act; the letter does not describe an inspection. FDA found no evidence of identity testing of incoming components or methanol testing of isopropyl alcohol, inadequate finished-product release testing, and an inadequate stability program for its Antibacterial Hand Sanitizer Gel. FDA placed the firm on Import Alert 66-40 on April 15, 2024.

What FDA found

  1. The firm did not test incoming drug components for identity and did not test its isopropyl alcohol active ingredient for methanol.

    21 CFR 211.84(d)(1)
  2. The firm did not show adequate finished-product release testing for identity and strength of isopropyl alcohol or for impurities, and did not provide test methods.

    21 CFR 211.165(a)
  3. The firm lacked an adequate stability program and data to support expiry, with results limited to color, clarity, odor, and pH.

    21 CFR 211.166(a)

What FDA wants

Respond in writing within 15 working days with what you have done to correct the violations and prevent recurrence. FDA also recommends engaging a qualified consultant before resuming U.S. drug manufacturing.

Who should pay attention

  • US brands and retailers selling OTC hand sanitizer made by this contract manufacturer
  • US importers and distributors of Malaysian drug products
  • quality teams at OTC drug and hand sanitizer manufacturers

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk